By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Saladax Biomedical said today that Eilaf Pharma will exclusively distribute the My5-FU diagnostic test in Egypt and the Middle East North African region.

Saladax's test allows physicians to determine optimal dosing of the 5-fluorouracil (5-FU) anti-cancer drug for patients, and is the first of the Bethlehem, Penn.-based firm's dose management tests to be commercially available.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: genomic study of group B Streptococcus evolution, selection on the X chromosome in great apes, and more.

In PLOS this week: genes under positive selection in Plasmodium falciparum populations, genetic variation in Epstein-Barr viruses, and more.

Cancer clinical trial patients settle with Anil Potti and Duke University.

A trio of researchers is trying to raise money to sequence and analyze the genome of a cat with a suite of unusual traits.